GlassScriptPhysician profile
Paula S Wolf
NPI 1407445950
$2,164.91
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $539 · 2023: $829 · 2024: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.57 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.44 | 2021-2023 | Synjardy, Jardiance |
| Novo Nordisk INC | $281.29 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $212.28 | 2022-2023 | Spravato |
| Lilly USA, LLC | $201.68 | 2021-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $149.40 | 2021-2023 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $106.84 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.22 | 2022-2023 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $58.81 | 2021-2023 | |
| Amgen INC. | $50.93 | 2022-2023 | Otezla, Repatha |
| Sanofi Pasteur INC. | $34.06 | 2021-2022 | |
| Redhill Biopharma INC. | $28.32 | 2021 | |
| Sumitomo Pharma America, INC. | $25.55 | 2023 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.86 | 2023 | Trulance, Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.22 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $17.02 | 2023 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceuticals, INC. | $16.99 | 2021 | |
| Axsome Therapeutics, INC. | $16.12 | 2022 | |
| Renalytix Ai, INC. | $15.72 | 2022 | |
| Lucid Diagnostics INC. | $14.50 | 2023 | |
| Merck Sharp & Dohme LLC | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.